Edesa Biotech, Inc. (EDSA)

Market Cap	49.76M +235.2%
Revenue (ttm)	n/a
Net Income	-7.82M
EPS	-1.14
Shares Out	8.35M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	620,173
Open	6.37
Previous Close	6.38
Day's Range	5.85 - 6.71
52-Week Range	0.72 - 8.74
Beta	0.05
Analysts	Strong Buy
Price Target	5.00 (-16.11%)
Earnings Date	Feb 13, 2026

About EDSA

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 17
• Stock Exchange: NASDAQ
• Ticker Symbol: EDSA
• Website: https://www.edesabiotech.com

Analyst Summary

According to one analyst, the rating for EDSA stock is "Strong Buy" and the 12-month stock price target is $5.0.

Price Target

$5.0

(-16.11% downside)

Analyst Consensus: Strong Buy